Table 1 Demographic, clinical and laboratory parameters
Parameter | Result | Normal range |
|---|---|---|
Age (year) a | 66.2 ± 8.3 | NA |
Gender b | Â | Â |
Male | 30 (93.8) | NA |
Female | 2 (6.3) | NA |
BMI (kg/m2) a | 24.2 ± 2.9 | NA |
History of smoking b | 28 (87.5) | NA |
Smoking Index a | 867.3 ± 546.3 | NA |
Pulmonary function before operation a | Â | Â |
FVC / Predicted Value (%) | 92.0 ± 13.8 | NA |
DLCO / Predicted Value (%) | 63.0 ± 15.0 | NA |
SpO2@RA (%) a | 96.5 ± 3.5 | NA |
Pathological classification b | Â | Â |
Adenocarcinoma | 16 (50.0) | NA |
Squamous cell carcinoma | 11 (34.4) | NA |
Small cell lung cancer | 3 (9.4) | NA |
Large cell neuroendocrine carcinoma | 1 (3.1) | NA |
Undifferentiated lung cancer | 1 (3.1) | NA |
Staging of lung cancer b | Â | Â |
Stage IA | 9 (28.1) | NA |
Stage IB | 5 (15.6) | NA |
Stage IIA | 2 (6.3) | NA |
Stage IIB | 10 (31.3) | NA |
Stage IIIA | 3 (9.4) | NA |
Stage IIIB | 1 (3.1) | NA |
Stage IVA | 2 (6.3) | NA |
NSE (ng/ml) a | 4.8 ± 3.5 | 0–5 |
CEA (ng/ml) a | 4.4 ± 3.0 | 0-3.5 |
Cyfra211 (ng/ml) a | 15.1 ± 3.8 | 0-16.3 |
SCCAg (ng/ml) a | 1.6 ± 1.8 | 0-2.7 |
ProGRP (pg/ml) a | 126.7 ± 336.8 | 0–50 |